|
FZD5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.33066907387547E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.88737914186277E-15 |
| Normal-vs-Stage2 |
5.304645611659E-13 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
6.869200E-01 |
| Stage1-vs-Stage3 |
1.393840E-01 |
| Stage1-vs-Stage4 |
1.32509999972719E-07 |
| Stage2-vs-Stage3 |
5.513800E-01 |
| Stage2-vs-Stage4 |
7.882800E-03 |
| Stage3-vs-Stage4 |
1.339240E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44089209850063E-16 |
| Normal-vs-AfricanAmerican |
1.90958360235527E-14 |
| Normal-vs-Asian |
8.32667268468867E-15 |
| Caucasian-vs-AfricanAmerican |
2.905600E-01 |
| Caucasian-vs-Asian |
9.919400E-01 |
| AfricanAmerican-vs-Asian |
3.008400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62503344114384E-12 |
| Male-vs-Female |
1.636170E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62680979798324E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.018720E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.992800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.498400E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.029600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.530300E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.231000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.306400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.704140E-02 |
| Classical-VS-Follicular |
9.607900E-02 |
| Classical-VS-Other |
6.349600E-01 |
| Classical-VS-Normal |
1.63102864547682E-12 |
| Tall-VS-Follicular |
4.564400E-01 |
| Tall-VS-Other |
3.866800E-01 |
| Tall-VS-Normal |
1.11022302462516E-16 |
| Follicular-VS-Other |
4.685600E-01 |
| Follicular-VS-Normal |
1.62458935193399E-12 |
| Other-VS-Normal |
5.220800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.44089209850063E-16 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
6.127700E-02 |
|
|
